Alzheimer's Disease and Parkinson's Disease
Open accessThe DOI matches its Crossref record; 106 of the 107 references it cites were found in a registry or an index.
Abstract
Although most cases of Alzheimer's and Parkinson's disease are sporadic, some cases are clearly familial. This review, part of the Genomic Medicine series, examines the genetics of these familial forms. Although the inherited forms are rare, the knowledge derived from investigating their pathobiology has improved our understanding of the pathobiology of the more common, sporadic forms of the diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In general terms, neurodegenerative diseases are thought to be driven by the accumulation of neurotoxic material such as amyloid beta (Aβ) or myelin debris in the central nervous system (CNS) (Nussbaum and Ellis, 2003; Trapp and Nave, 2008).”
From SYK coordinates neuroprotective microglial responses in neurodegenerative disease (2022) · cites this paper as Nussbaum and Ellis, 2003
In the citing paper
“PD pathology is mainly characterized by loss of neurons from the substantia nigra pars compacta in association with the accumulation of ubiquitinated alpha synuclein and other proteins in cytoplasmic inclusions (Lewy bodies) and thread-like proteinaceous inclusions within neurites (Lewy neuritis).”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [4]
In the citing paper
“However, Lewy bodies are also seen in the cerebral cortex, brainstem nuclei, limbic system, sympathetic ganglia, nucleus basalis of Meinert and myenteric plexus [4].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [4]
In the citing paper
“This review is focused on the potential of herbal medicine in AD since it is responsible for more than two-thirds of all dementia cases [5,6].”
From Indian Medicinal Herbs and Formulations for Alzheimer’s Disease, from Traditional Knowledge to Scientific Assessment (2020) · cites this paper as [6]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378 · cited 4×
“Increased Abeta42(43) from cell lines expressing presenilin 1 mutations.”
BackgroundInfluentialSpillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Self-citationMutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Research works printed but not linked: 5
- 10.1001/archinte.151.5.989 · doi:10.1001/archinte.151.5.989 · Paper page
- Clark CM, Ewbank D, Lee VM-Y, Trojanowski JQ. Molecular pathology of Alzheimer's disease: neuronal cytoskeletal abnormalities. In: Growdon JH, Rossor MN, eds. The dementias. Vol. 19 of Blue books of practical neurology. Boston: Butterworth–Heinemann, 1998:285-304.
- Duvoisin RC, 1996, Adv Neurol, 69, 33
- Louis ED, 1996, Adv Neurol, 69, 311
- Matsumine H, 1997, Am J Hum Genet, 60, 588
Cited by
Items 101–200 of 1,000
Curcumin and neurodegenerative diseases
Monroy, A., Lithgow, G. J., & Alavez, S. (2013) · BioFactors · doi:10.1002/biof.1063 · Cited by 172
Fang, X., Han, D., Cheng, Q., Zhang, P., Zhao, C., Min, J., & Wang, F. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.2421 · Cited by 171
Molecular Genetics of Late‐Onset Alzheimer's Disease
Kamboh, M. I. (2004) · Annals of Human Genetics · doi:10.1046/j.1529-8817.2004.00110.x · Cited by 170
“Overall, AD accounts for about two thirds of subjects with dementia (Nussbaum & Ellis, 2003).”
BackgroundRole of Mitogen Activated Protein Kinase Signaling in Parkinson’s Disease
Bohush, A., Niewiadomska, G., & Filipek, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102973 · Cited by 177
“Parkinson’s disease (PD) is a neurodegenerative disorder of the central nervous system (CNS), which affects about 1% of human population over the age of 60 [1] around the world and, for which, up to now, no cure has been developed [2].”
BackgroundCalcium dysregulation in Alzheimer's disease: From mechanisms to therapeutic opportunities
Yu, J.-T., Chang, R. C.-C., & Tan, L. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.07.009 · Cited by 168
The Role of Diet as a Modulator of the Inflammatory Process in the Neurological Diseases
Kurowska, A., Ziemichód, W., Herbet, M., & Piątkowska‐Chmiel, I. (2023) · Nutrients · doi:10.3390/nu15061436 · Cited by 183
“Furthermore, genetic factors also play a significant role in the pathogenesis of this disease [120].”
BackgroundYin, G., Gan, Y., Jiang, H., Yu, T., Liu, M., Zhang, Y., Li, H., Yin, P., & Yao, S. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c01945 · Cited by 167
Soreq, L., Guffanti, A., Salomonis, N., Simchovitz, A., Israel, Z., Bergman, H., & Soreq, H. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003517 · Cited by 165
“PD is the second most common neurodegenerative disease worldwide (after AD) [14,15], with age being the leading risk factor currently known and no known cure.”
BackgroundBa, F., & Martin, W. R. W. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.11.007 · Cited by 160
“Its estimated prevalence is close to 1% in those aged 65e69 years, and increases with age [1].”
BackgroundInflammation, Neurodegenerative Diseases, and Environmental Exposures
CAMPBELL, A. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1332.008 · Cited by 163
The Role of the Gut Microbiota in the Pathogenesis of Parkinson's Disease
Yang, D., Zhao, D., Ali Shah, S. Z., Wu, W., Lai, M., Zhang, X., Li, J., Guan, Z., Zhao, H., Li, W., et al. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01155 · Cited by 162
Walsh, S. R., Finn, D. P., & Dowd, E. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.12.005 · Cited by 160
Ho, C., Troncoso, J. C., Knox, D., Stark, W., & Eberhart, C. G. (2014) · Brain Pathology · doi:10.1111/bpa.12070 · Cited by 159
Cardiac abnormalities in Parkinson’s disease and Parkinsonism
Scorza, F. A., Fiorini, A. C., Scorza, C. A., & Finsterer, J. (2018) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2018.04.031 · Cited by 151
Ulmer, T. S., & Bax, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507624200 · Cited by 145
Advances in nanotechnology and nanomaterials based strategies for neural tissue engineering
Kumar, R., Aadil, K. R., Ranjan, S., & Kumar, V. B. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.101617 · Cited by 164
Freimer, N. B., & Sabatti, C. (2004) · Nature Genetics · doi:10.1038/ng1433 · Cited by 167
“For common diseases, the extended pedigree approach has so far failed, other than for rare early-onset forms of these diseases, to fulfill the expectation that it would identify high-penetrance variants that illuminate biological pathway”
BackgroundRodríguez-Rodríguez, C., Telpoukhovskaia, M., & Orvig, C. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2012.03.008 · Cited by 151
Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases
Staff, N. P., Jones, D. T., & Singer, W. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.01.001 · Cited by 150
Marshall, S. (2008) · Traffic Injury Prevention · doi:10.1080/15389580801895244 · Cited by 163
Cooray, R., Gupta, V. B., & Suphioglu, C. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02054-6 · Cited by 163
“The genetic studies describe that the mutations in α-synuclein [5, 6], PINK1 [7], DJ-1 (PARK7) [8, 9], ubiquitin genes such as ubiquitin-C-hydrolase [10, 11], and population-specific gene mutations such as glucocerebrosidase gene in Ashkenazi Jews [12] directly relate to the onset of PD [13].”
BackgroundKim, S. Y., Buckwalter, M., Soreq, H., Vezzani, A., & Kaufer, D. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2012.03701.x · Cited by 145
Genetic overlap between Alzheimer’s disease and Parkinson’s disease at the MAPT locus
Desikan, R. S., Schork, A. J., Wang, Y., Witoelar, A., Sharma, M., McEvoy, L. K., Holland, D., Brewer, J. B., Chen, C.-H., Thompson, W. K., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.6 · Cited by 148
Yin, G. N., Lee, H. W., Cho, J.-Y., & Suk, K. (2009) · Brain Research · doi:10.1016/j.brainres.2009.01.058 · Cited by 143
Dominantly Inherited Alzheimer Network: facilitating research and clinical trials
Moulder, K. L., Snider, B., Mills, S. L., Buckles, V. D., Santacruz, A. M., Bateman, R. J., & Morris, J. C. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt213 · Cited by 142
“Although ADAD accounts for less than 1% of all AD cases [16], its clinical and pathological phenotypes are largely similar to those of sporadic, lateonset AD (LOAD) [17,18].”
BackgroundHolmans, P., Moskvina, V., Jones, L., Sharma, M., The International Parkinson's Disease Genomics Consortium (IPDGC), Vedernikov, A., Buchel, F., Sadd, M., Bras, J. M., Bettella, F., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/dds492 · Cited by 139
Clinical 7 T MRI: Are we there yet? A review about magnetic resonance imaging at ultra-high field
Barisano, G., Sepehrband, F., Ma, S. J., Jann, K., Cabeen, R. P., Wang, D. J. J., Toga, A. W., & Law, M. (2018) · British Journal of Radiology · doi:10.1259/bjr.20180492 · Cited by 151
Intranasal Administration of TAT-Conjugated Lipid Nanocarriers Loading GDNF for Parkinson’s Disease
Hernando, S., Herrán, E., Figueiro‐Silva, J., Pedraz, J. L., Igartúa, M., Carro, E., & Hernández, R. M. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0728-7 · Cited by 142
Vauzour, D. (2014) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.6473 · Cited by 135
The Role and Therapeutic Targeting of α-, β- and γ-Secretase in Alzheimer's Disease
MacLeod, R., Hillert, E.-K., Cameron, R. T., & Baillie, G. S. (2015) · Future Science OA · doi:10.4155/fso.15.9 · Cited by 125
Monje, M. H. G., Foffani, G., Obeso, J. A., & Sánchez‐Ferro, Á. (2019) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-062117-121036 · Cited by 147
Ariga, T., Miyatake, T., & Yu, R. K. (2010) · Journal of Neuroscience Research · doi:10.1002/jnr.22393 · Cited by 127
Sibille, E. (2013) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2013.15.1/esibille · Cited by 130
Comparisons of telomere lengths in peripheral blood and cerebellum in Alzheimer's disease
Lukens, J. N., Van Deerlin, V., Clark, C. M., Xie, S. X., & Johnson, F. B. (2009) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2009.05.666 · Cited by 128
Zabetian, C. P., Hutter, C. M., Yearout, D., Lopez, A. N., Factor, S. A., Griffith, A., Leis, B. C., Bird, T. D., Nutt, J. G., Higgins, D. S., et al. (2006) · The American Journal of Human Genetics · doi:10.1086/508025 · Cited by 140
Casein kinase 1α: biological mechanisms and theranostic potential
Jiang, S., Zhang, M., Sun, J., & Yang, X. (2018) · Cell Communication and Signaling · doi:10.1186/s12964-018-0236-z · Cited by 130
Integrated molecular landscape of Parkinson’s disease
Klemann, C. J. H. M., Martens, G. J. M., Sharma, M., Martens, M. B., Isacson, O., Gasser, T., Visser, J. E., & Poelmans, G. (2017) · npj Parkinson's Disease · doi:10.1038/s41531-017-0015-3 · Cited by 123
“In the present study, we aimed to identify the core mechanisms underlying PD pathogenesis by using bioinformatics and extensive literature analyses to integrate (1) the genes corresponding to the top-ranked single-nucleotide polymorphisms (SNPs) found in published GWASs of sporadic PD, and (2) other PD candidate genes…”
BackgroundMethodInfluentialVision-based assessment of parkinsonism and levodopa-induced dyskinesia with pose estimation
Li, M. H., Mestre, T. A., Fox, S. H., & Taati, B. (2018) · Journal of NeuroEngineering and Rehabilitation · doi:10.1186/s12984-018-0446-z · Cited by 123
Genetic Factors in Alzheimer's Disease
Bird, T. D. (2005) · New England Journal of Medicine · doi:10.1056/nejmp058027 · Cited by 121
Cognition, language, and clinical pathological features of non-Alzheimer's dementias: An overview
Reilly, J., Rodriguez, A. D., Lamy, M., & Neils-Strunjas, J. (2010) · Journal of Communication Disorders · doi:10.1016/j.jcomdis.2010.04.011 · Cited by 119
Apolipoprotein E and Dementia in Parkinson Disease: A Meta-analysis
Huang, X., Chen, P., Kaufer, D. I., Tröster, A. I., & Poole, C. (2006) · Archives of Neurology · doi:10.1001/archneur.63.2.189 · Cited by 128
“by neuronal death and protein deposition (eg, amyloid or -synuclein).(5)”
BackgroundProgress in Stem Cell Therapy for Major Human Neurological Disorders
Martínez‐Morales, P., Revilla, A., Ocaña, I., González, C., Sainz, P., McGuire, D., & Liste, I. (2013) · Stem Cell Reviews and Reports · doi:10.1007/s12015-013-9443-6 · Cited by 134
Hybrid FMT–CT imaging of amyloid-β plaques in a murine Alzheimer's disease model
Hyde, D. E., DEKLEINE, R., MacLaurin, S. A., Miller, E. L., BROOKS, D., Krucker, T., & Ntziachristos, V. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.10.038 · Cited by 134
“From an average onset of 80 years, AD incidence increases exponentially, with more than 50% of 90–95 year old individuals likely being symptomatic (Nussbaum and Ellis, 2003).”
The role of innate immunity in Alzheimer's disease
Ennerfelt, H. E., & Lukens, J. R. (2020) · Immunological Reviews · doi:10.1111/imr.12896 · Cited by 119
Dong, Z., Ferger, B., Paterna, J.-C., Vogel, D., Furler, S., Osinde, M., Feldon, J., & Büeler, H. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2132992100 · Cited by 124
Brain targeted nanoparticulate drug delivery system of rasagiline via intranasal route
Mittal, D., Md, S., Hasan, Q., Fazil, M., Ali, A., Baboota, S., & Ali, J. (2016) · Drug Delivery · doi:10.3109/10717544.2014.907372 · Cited by 117
“Parkinson’s disease (PD) is a progressive neurological disorder which affect around 2% of adults over the age of 60 years (Nussbaum & Ellis, 2003).”
BackgroundLatent toxoplasmosis and human.
Dalimi, A., & Abdoli, A. (2012) · PubMed Central · Cited by 154
Flanagan, E., Müller, M., Hornberger, M., & Vauzour, D. (2018) · Current Nutrition Reports · doi:10.1007/s13668-018-0226-1 · Cited by 115
“By contrast, in the Kame project, a more frequent consumption of flavonoids-rich foods was suggested to delay the onset of AD particularly in APOE4 carriers [31]. As such, further investigation is required in order to elucidate the exact mechanisms by which the presence of the APOE4 mutation modulates the health benef…”
Comparison of Family History and SNPs for Predicting Risk of Complex Disease
Do, C. B., Hinds, D. A., Francke, U., & Eriksson, N. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002973 · Cited by 130
Molecular mechanisms of α-synuclein and GBA1 in Parkinson’s disease
Stojkovska, I., Krainc, D., & Mazzulli, J. R. (2018) · Cell and Tissue Research · doi:10.1007/s00441-017-2704-y · Cited by 110
“Parkinson’s disease (PD) is the most prevalent motor disease and second most common neurodegenerative disorder, affecting about 1% of people over 60 years of age (Nussbaum and Ellis 2003).”
Protein misfolding and amyloid nucleation through liquid–liquid phase separation
Mukherjee, S., Poudyal, M., Dave, K., Kadu, P., & Maji, S. K. (2024) · Chemical Society Reviews · doi:10.1039/d3cs01065a · Cited by 124
Luquín, M. R., Kulisevsky, J., Martínez‐Martín, P., Mir, P., & TOLOSA, E. S. (2017) · Parkinson s Disease · doi:10.1155/2017/4047392 · Cited by 123
Parkinson’s disease: experimental models and reality
Jiang, P., & Dickson, D. W. (2018) · Acta Neuropathologica · doi:10.1007/s00401-017-1788-5 · Cited by 111
Qiu, C. (2004) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.021493 · Cited by 110
Wang, Z., Liu, J., Zhu, Z., Su, C.-F., Sreenivasmurthy, S. G., Iyaswamy, A., Lu, J., Chen, G., Song, J., & Li, M. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110968 · Cited by 118
Simard, A. R., & Rivest, S. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001809 · Cited by 126
Monoamine oxidases in age-associated diseases: New perspectives for old enzymes
Santin, Y., Resta, J., Parini, A., & Mialet-Perez, J. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101256 · Cited by 105
Grimm, S., Hoehn, A., Davies, K. J., & Grune, T. (2011) · Free Radical Research · doi:10.3109/10715762.2010.512040 · Cited by 107
Bao, F., Wicklund, L., Lacor, P. N., Klein, W. L., Nordberg, A. K., & Marutle, A. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.05.003 · Cited by 129
“Age is the most significant risk factor for AD (Kawas, 2003; Nussbaum and Ellis, 2003).”
BackgroundVellata, C., Belli, S., Balsamo, F., Giordano, A., Colombo, R., & Maggioni, G. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.627999 · Cited by 122
“The first category dealt with the effect of TR on gait and balance (3), dexterity of the upper limbs (3), and bradykinesia (0).”
BackgroundInfluentialA large study reveals no association between APOE and Parkinson's disease
Federoff, M., Jimenez-Rolando, B., Nalls, M. A., & Singleton, A. B. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.02.002 · Cited by 105
“Parkinson's disease (PD), with a prevalence of approximately 2% of the adult population over 65 years of age, is second to Alzheimer's Disease (AD) as the most common neurodegenerative disorder (Nussbaum and Ellis, 2003).”
BackgroundEvidence of a Role for Lactadherin in Alzheimer's Disease
Boddaert, J., Kinugawa, K., Lambert, J., Boukhtouche, F., Zoll, J., Merval, R., Blanc‐Brude, O., Mann, D. M. A., Berr, C., Vilar, J., et al. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.060664 · Cited by 114
Mehla, J., Gupta, P., Pahuja, M., Diwan, D., & Diksha, D. (2020) · Brain Sciences · doi:10.3390/brainsci10120964 · Cited by 108
“This review is focused on the potential of herbal medicine in AD since it is responsible for more than two-thirds of all dementia cases [5,6].”
BackgroundElectrical Stimuli in the Central Nervous System Microenvironment
Thompson, D. M., Koppes, A. N., Hardy, J. G., & Schmidt, C. E. (2014) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-121813-120655 · Cited by 107
Wang, Y., Strickland, C., Voigt, J. H., Kennedy, M. E., Beyer, B. M., Senior, M. M., Smith, E. M., Nechuta, T. L., Madison, V., Czarniecki, M., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901472u · Cited by 118
The Development of New Therapeutics for Alzheimer's Disease
Carter, M. D., Simms, G. A., & Weaver, D. F. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.165 · Cited by 105
Exercise Guidelines for Gait Function in Parkinson’s Disease: A Systematic Review and Meta-analysis
Ni, M., Hazzard, J. B., Signorile, J. F., & Luca, C. C. (2018) · Neurorehabilitation and neural repair · doi:10.1177/1545968318801558 · Cited by 120
Franco, G. A., Interdonato, L., Cordaro, M., Cuzzocrea, S., & Paola, R. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087318 · Cited by 116
“Despite the distinctions in etiology between the two diseases, they are both classic neurodegenerative diseases marked by the chronic, progressive loss of neurons and their synaptic connections, which manifests as a steady deterioration in functional ability [4].”
BackgroundPower training induced change in bradykinesia and muscle power in Parkinson's disease
Ni, M., Signorile, J. F., Balachandran, A. T., & Potiaumpai, M. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.11.028 · Cited by 129
Photoswitchable peptides for spatiotemporal control of biological functions
Albert, L., & Vázquez, O. (2019) · Chemical Communications · doi:10.1039/c9cc03346g · Cited by 110
Inflammation, genes and zinc in Alzheimer's disease
Vasto, S., Candore, G., Listì, F., Balistreri, C. R., Colonna‐Romano, G., Malavolta, M., Lio, D., Nuzzo, D., Mocchegiani, E., Bona, D. D., et al. (2008) · Brain Research Reviews · doi:10.1016/j.brainresrev.2007.12.001 · Cited by 121
“This peptide is highly neurotoxic especially, due to the self aggregation and its capacity to form insoluble plaques either in vitro or in vivo (Nussbaum and Ellis, 2003; Findeis, 2007; Newman et al., 2007).”
InfluentialWang, Y., Liu, W., Zhang, Q., Zhao, H., & Quan, X. (2015) · Food and Chemical Toxicology · doi:10.1016/j.fct.2014.12.008 · Cited by 93
Glorioso, C., Oh, S., Douillard, G. G., & Sibille, E. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.09.016 · Cited by 103
“…neurodegenerative diseases such as Alzheimer's and Parkinson's diseases (mean age at diagnosis ~70 (Van Den Eeden et al., 2003) and ~80 years (Nussbaum and Ellis, 2003), respectively) to earlier onset psychiatric disorders such as schizophrenia andbipolardisorder (averageonset ~25 years)…”
BackgroundInfluentialHardy, J. (2005) · Biochemical Society Transactions · doi:10.1042/bst0330578 · Cited by 105
Hanyu, H., Shimizu, S., Hirao, K., Kanetaka, H., Iwamoto, T., Chikamori, T., Usui, Y., Yamashina, A., Koizumi, K., & Abe, K. (2005) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-005-1921-x · Cited by 107
Taschenberger, G., Garrido, M., Tereshchenko, Y., Bähr, M., Zweckstetter, M., & Kügler, S. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0926-8 · Cited by 98
Gut bacterial composition in a mouse model of Parkinson’s disease
Perez-Pardo, P., Dodiya, H. B., Engen, P. A., Naqib, A., Forsyth, C. B., Green, S. J., Garssen, J., Keshavarzian, A., & Kraneveld, A. D. (2018) · Beneficial Microbes · doi:10.3920/bm2017.0202 · Cited by 102
“Parkinson’s disease (PD) is the second most common adult neurodegenerative disease after Alzheimer’s disease, characterised by motor impairments due to defects in motor control (De Rijk et al., 2000; Nussbaum and Ellis, 2003).”
Prado Lima, M. G., Schimidt, H. L., Garcia, A., Daré, L. R., Carpes, F. P., Izquierdo, I., & Mello-Carpes, P. B. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718435115 · Cited by 96
α-Synuclein Populates Both Elongated and Broken Helix States on Small Unilamellar Vesicles
Lokappa, S. B., & Ulmer, T. S. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.224055 · Cited by 94
Post, B., Muslimović, D., van Geloven, N., Speelman, J. D., Schmand, B. A., de Haan, R. J., & on behalf of the CARPA‐study group (2011) · Movement Disorders · doi:10.1002/mds.23467 · Cited by 102
Mediterranean Dietary Pattern at Middle Age and Risk of Parkinson's Disease: A Swedish Cohort Study
Yin, W., Löf, M., Pedersen, N. L., Sandin, S., & Fang, F. (2021) · Movement Disorders · doi:10.1002/mds.28314 · Cited by 92
“Parkinson’s disease (PD) is the second most common neurodegenerative disease worldwide, affecting approximately 1% of the population older than 60 years in Europe.1,2 Despite our increasing knowledge about risk and protective factors, causes of PD remain largely unclear for the majority of patients.3 Earlier studies h…”
BackgroundAssociation of GSK3B with Alzheimer disease and frontotemporal dementia
Schaffer, B. A. J., Bertram, L., Miller, B. L., Mullin, K., Weintraub, S., Johnson, N., Bigio, E. H., Mesulam, M., Wiedau-Pazos, M., Jackson, G. R., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.10.1368 · Cited by 100
α-Synuclein Multistate Folding Thermodynamics: Implications for Protein Misfolding and Aggregation
Ferreon, A. C. M., & Deniz, A. A. (2007) · Biochemistry · doi:10.1021/bi602461y · Cited by 103
Emerging concepts in neural stem cell research: autologous repair and cell-based disease modelling
Koch, P., Kokaia, Z., Lindvall, O., & Brüstle, O. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70202-9 · Cited by 110
Rodrigues, T. M., Caldas, A. C., & Ferreira, J. J. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.03.002 · Cited by 105
Eltoukhy, M. A., Kuenze, C. M., Oh, J., Jacopetti, M., Wooten, S. V., & Signorile, J. F. (2017) · Medical Engineering & Physics · doi:10.1016/j.medengphy.2017.03.007 · Cited by 97
Hierarchical chemical determination of amyloid polymorphs in neurodegenerative disease
Li, D., & Liu, C. (2021) · Nature Chemical Biology · doi:10.1038/s41589-020-00708-z · Cited by 98
Inferring new indications for approved drugs via random walk on drug-disease heterogenous networks
Liu, H., Song, Y., Guan, J., Luo, L., & Zhuang, Z. (2016) · BMC Bioinformatics · doi:10.1186/s12859-016-1336-7 · Cited by 92
Zesiewicz, T. (2019) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000764 · Cited by 129
Integral UBL domain proteins: a family of proteasome interacting proteins
Hartmann‐Petersen, R., & Gordon, C. (2004) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2003.12.006 · Cited by 108
Candore, G., Bulati, M., Caruso, C., Castiglia, L., Colonna-Romano, G., Di Bona, D., Duro, G., Lio, D., Matranga, D., Pellicanò, M., et al. (2010) · Rejuvenation Research · doi:10.1089/rej.2009.0993 · Cited by 92
E ffect of levodopa‐carbidopa intestinal gel on dyskinesia in advanced P arkinson's disease patients
Antonini, A., Fung, V. S. C., Boyd, J. T., Slevin, J. T., Hall, C. M., Chatamra, K., Eaton, S., & Benesh, J. A. (2016) · Movement Disorders · doi:10.1002/mds.26528 · Cited by 93
“Parkinson’s disease (PD) is a common neurodegenerative disorder(1) characterized by a progressive depletion of dopaminergic neurons in the nigrostriatal system(2) and motor dysfunctions such as bradykinesia, rigidity, tremor, and postural instability.(1) Immediate release oral levodopa-carbidopa (LC-IR) is the leading…”
BackgroundMok, K. Y., Sheerin, U., Simón‐Sánchez, J., Salaka, A. S., Chester, L. A., Escott‐Price, V., Mantripragada, K. K., Doherty, K. A., Noyce, A. J., Mencacci, N. E., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00071-5 · Cited by 97
Sex difference in human diseases: mechanistic insights and clinical implications
Shi, Y., Ma, J., Li, S., Liu, C., Liu, Y., Chen, J., Liu, N., Liu, S., & Huang, H. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01929-7 · Cited by 95
Limelight on Alpha-Synuclein: Pathological and Mechanistic Implications in Neurodegeneration
Wales, P., Pinho, R., Lázaro, D. F., & Outeiro, T. F. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130216 · Cited by 86
Controlled pilot study of the effects of power yoga in Parkinson’s disease
Ni, M., Mooney, K., & Signorile, J. F. (2016) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2016.01.007 · Cited by 101
The Fly as a Model for Neurodegenerative Diseases: Is It Worth the Jump?
Cauchi, R. J., & van den Heuvel, M. (2006) · Neurodegenerative Diseases · doi:10.1159/000097303 · Cited by 88
Rasmi, Y., Shokati, A., Hassan, A., Aziz, S. G., Bastani, S., Jalali, L., Moradi, F., & Alipour, S. (2022) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2022.12.002 · Cited by 96
Neirinckx, V., Coste, C., Rogister, B., & Wislet-Gendebien, S. (2013) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0147 · Cited by 89
Callens, M., Kraskovskaya, N., Derevtsova, K. Z., Annaert, W. G., Bultynck, G., Борисович, Б. И., & Vervliet, T. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2021.118997 · Cited by 93
Metadata
- Authors
- Nussbaum, R. L., & Ellis, C. E.
- Affiliations
- National Institutes of Health (US)
- ORCID
- Nussbaum, Robert L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-04-03
- Volume
- 348
- Issue
- 14
- Pages
- 1356-1364
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2149522871
- Cited by
- 1,351
- References
- 107
- Citations by year
- 2026: 25 · 2025: 55 · 2024: 75 · 2023: 74 · 2022: 80 · 2021: 82 · 2020: 80 · 2019: 83 · 2018: 74 · 2017: 74 · 2016: 63 · 2015: 54 · 2014: 65 · 2013: 46 · 2012: 66
- FWCI
- 5.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- DigitalGeorgetown (Georgetown University Library) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- Alzheimer's disease, Parkinson's disease, genetic susceptibility, inherited neurodegenerative disorders
- MeSH terms
- Alzheimer Disease, Amino Acid Sequence, Apolipoproteins E, Humans, Molecular Sequence Data, Nerve Tissue Proteins, Substantia Nigra, Prevalence, Amyloid beta-Protein Precursor, Lewy Bodies, Mutation, Missense, Parkinsonian Disorders, Synucleins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.